Gamma-Knife-based stereotactic radiosurgery for uveal melanoma

Achilles J. Fakiris, Simon S. Lo, Mark A. Henderson, Thomas C. Witt, Robert M. Worth, Ronald P. Danis, Paul M. Des Rosiers, Robert D. Timmerman

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Nineteen patients with uveal melanoma were treated with Gamma-Knife-based stereotactic radiosurgery (SRS). The radiation dose was 40 Gy prescribed to the 50% isodose line for all patients. The median follow-up was 40 months. The 3- and 5-year overall survival rates were 86 and 55%, respectively. The 3- and 5-year tumor control rates were both 94%. Six of the 19 treated patients (32%) developed distant metastasis 31-75 months after SRS. Out of the 19 patients treated with SRS, 2 had improved, 4 had stable and 13 had worse vision in the treated eye. Gamma-Knife-based SRS appears to provide excellent local control of uveal melanoma. The risk of distant metastasis is significant. Effective systemic therapy is to be explored to improve the treatment outcome of uveal melanoma.

Original languageEnglish (US)
Pages (from-to)106-112
Number of pages7
JournalStereotactic and Functional Neurosurgery
Issue number2-3
StatePublished - Mar 2007


  • Gamma Knife
  • Stereotactic radiosurgery
  • Uveal melanoma

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology


Dive into the research topics of 'Gamma-Knife-based stereotactic radiosurgery for uveal melanoma'. Together they form a unique fingerprint.

Cite this